Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001867264 | SCV002122001 | pathogenic | not provided | 2023-06-06 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant has not been reported in the literature in individuals affected with SEPSECS-related conditions. This variant is present in population databases (rs781277383, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Glu343Cysfs*9) in the SEPSECS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SEPSECS are known to be pathogenic (PMID: 25558065, 25590979, 26115735). |
New York Genome Center | RCV002266042 | SCV002548827 | likely pathogenic | Pontocerebellar hypoplasia type 2D | 2021-08-13 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV002266042 | SCV003815753 | likely pathogenic | Pontocerebellar hypoplasia type 2D | 2022-06-29 | criteria provided, single submitter | clinical testing |